Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 500 of 3499 entries
View as:

Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00096070 Org: User:
Start: 12/31/04 End: - Due: -

Cervix Image Sharing Protocol (CISP)

Phase: N/A Priority: Normal
NCT ID: NCT03179306 Org: User:
Start: 05/15/17 End: 04/22/20 Due: 04/22/21

Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial

Phase: N/A Priority: Normal
NCT ID: NCT05361811 Org: User:
Start: 01/10/24 End: 12/31/25 Due: 12/31/26

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

Phase: N/A Priority: Normal
NCT ID: NCT01849250 Org: User:
Start: 05/31/13 End: 04/22/20 Due: 04/22/21

Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood

Phase: N/A Priority: Normal
NCT ID: NCT00923910 Org: User:
Start: 02/22/08 End: 11/15/16 Due: 11/15/17

Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic Vaccines

Phase: N/A Priority: Normal
NCT ID: NCT00001210 Org: User:
Start: 11/30/86 End: 09/30/00 Due: 09/30/01

CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00086840 Org: User:
Start: 05/31/04 End: - Due: -

Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00003210 Org: User:
Start: 02/28/98 End: 11/30/03 Due: 11/30/04

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

Phase: N/A Priority: Normal
NCT ID: NCT01989546 Org: User:
Start: 02/04/14 End: 03/26/20 Due: 03/26/21

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

Phase: N/A Priority: Normal
NCT ID: NCT04334941 Org: User:
Start: 07/20/20 End: 11/30/25 Due: 11/30/26

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Phase: N/A Priority: Normal
NCT ID: NCT06357975 Org: User:
Start: 05/30/16 End: 11/15/25 Due: 11/15/26

Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

Phase: N/A Priority: Normal
NCT ID: NCT00783705 Org: User:
Start: 11/30/08 End: 05/31/14 Due: 05/31/15

Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers

Phase: N/A Priority: Normal
NCT ID: NCT00001693 Org: User:
Start: 03/31/98 End: 01/31/02 Due: 01/31/03

Relationship Stressors in Parents of Children With Cancer or Neurofibromatosis Type 1 (NF1)

Phase: N/A Priority: Normal
NCT ID: NCT01702922 Org: User:
Start: 09/13/12 End: 12/07/20 Due: 12/07/21

SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00009919 Org: User:
Start: 12/31/00 End: - Due: -

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT06344130 Org: User:
Start: 10/01/24 End: 12/31/27 Due: 12/31/28

Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06161506 Org: User:
Start: 02/15/24 End: 03/01/26 Due: 03/01/27

Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00957905 Org: User:
Start: 06/30/09 End: 08/31/14 Due: 08/31/15

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03448393 Org: User:
Start: 03/26/18 End: 01/13/25 Due: 01/13/26

Imatinib Mesylate in Treating Patients With Recurrent Meningioma

Phase: N/A Priority: Normal
NCT ID: NCT00045734 Org: User:
Start: 02/28/03 End: 12/31/09 Due: 12/31/10

TRC105 for Liver Cancer That Has Not Responded to Sorafenib

Phase: N/A Priority: Normal
NCT ID: NCT01375569 Org: User:
Start: 06/22/11 End: 12/01/15 Due: 12/01/16

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06696768 Org: User:
Start: 01/23/26 End: 12/31/26 Due: 12/31/27

Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT03772925 Org: User:
Start: 06/20/19 End: 05/08/25 Due: 05/08/26

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00255762 Org: User:
Start: 12/31/05 End: - Due: -

AMG 386 and Abiraterone for Advanced Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01553188 Org: User:
Start: 02/08/12 End: 07/01/18 Due: 07/01/19